ImmunityBio will part with 10 employees this quarter. Last fall, it cut 31 employees. The moves come as the biotech works to advance Anktiva in non-small cell lung cancer.

Armando, a 71-year-old with an active lifestyle, was midway through a round of golf when a strange sensation crept into his ...

ImmunityBio, Inc.'s Anktiva shows promise for solid tumors, with growing sales and financing boosting growth potential. Click ...

A new report dives into the evolving clinical trial landscape and transformative therapies changing lives for bladder cancer ...

A “game-changer” study claims bladder cancer patients given an immunotherapy drug are a third less likely to see disease come back and are more likely to survive. Patients with advanced ...

Dr. David A. Braun delved into the molecular factors which drive exceptional responses to immunotherapy in metastatic clear cell renal cell carcinoma.

Professor Meghan Morrissey earns an innovation award to program immune cells to attack cancer tumors. #immunotherapy ...

She is also the chief medical officer of the lab consultancy firm Blood Associates, LLC. Bladder cancer occurs when cancerous cells form in the tissues of the bladder, the hollow organ in your ...

A recent study finds that sequential gemcitabine/docetaxel treatment offers better outcomes than additional BCG therapy for ...

A combination therapy of two drugs — a statin and a protein inhibitor — may help suppress the creation and growth of tumors ...

Objective response rate: The percentage of patients whose cancer shrinks or disappears after treatment. Bacillus Calmette-Guérin (BCG): A type of immunotherapy used to treat bladder cancer by ...

Innovative fluorescence-based diagnostic system identifies early-stage bladder cancer with 90% accuracy, utilizing untreated ...